Intra-Cellular Therapies

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm’s lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Intra-Cellular Therapies (ITCI) reports stellar Q4 performance and eyes market expansion

Intra-Cellular Therapies (ITCI) delivered strong financial performance in Q4 2022, driven by robust sales growth of CAPLYTA and a focus on expanding clinical programs.
While facing challenges in managing expenses and navigating market dynamics, the company is well-positioned to capitalize on opportunities in new indications and patient education initiatives.
ITCI's strategic investments in innovation and market expansion underscore its commitment to long-term growth and addressing mental health needs through novel treatment options.

Intra-Cellular Therapies reports robust Q1 performance and growth prospects

ITCI's strong Q1 performance driven by CAPLYTA and promising results from lumateperone studies position the company well for future growth.
Addressing unmet needs in MDD and bipolar depression, along with ongoing pipeline progress, showcases ITCI's commitment to innovation in neuropsychiatric treatments.
While facing challenges in market share data and increasing expenses, opportunities lie in expanding sales force, new indications for pipeline programs, and driving awareness for CAPLYTA.

Intra-Cellular Therapies (ITCI) reports strong Q2 performance and expands treatment portfolio

Intra-Cellular Therapies (ITCI) demonstrated robust performance in Q2, driven by strong revenue growth and promising developments in its product portfolio.
The company's financial strength, innovative pipeline, and focus on addressing unmet medical needs position it well for future growth and success.
While facing challenges in revenue guidance clarity and resource allocation, ITCI has opportunities to expand its market reach and improve patient outcomes.
By leveraging its strengths and addressing challenges effectively, Intra-Cellular Therapies (ITCI) can capitalize on opportunities to drive continued growth and innovation.

Intra-Cellular Therapies (ITCI) excels in Q3, eyes market expansion

Intra-Cellular Therapies (ITCI) showcased strong financial performance and growth prospects in Q3 2023, driven by CAPLYTA's success and pipeline advancements.
While the company faces challenges in sustaining growth and navigating regulatory complexities, opportunities in market expansion and innovation are key for future success.
ITCI's focus on expanding indications, clinical advancements, and financial strength position it well for continued growth and leadership in the pharmaceutical industry.

Intra-Cellular Therapies (ITCI) reports robust growth and strategic expansion

Intra-Cellular Therapies (ITCI) delivered a strong performance in 2023, with robust revenue growth and strategic plans for pipeline advancement and market expansion.
The company faces challenges in managing expenses, optimizing market penetration, and navigating competitive dynamics, but opportunities in sales growth and innovation are evident.
Overall, Intra-Cellular Therapies (ITCI) is well-positioned for continued success, with a focus on driving growth through product differentiation and market positioning.

Intra-Cellular Therapies (ITCI) reports strong Q1 earnings and eyes market expansion

Intra-Cellular Therapies (ITCI) delivered strong Q1 2024 earnings driven by robust CAPLYTA sales and positive results in MDD studies, positioning the company for future growth.
With a solid financial position, a broad label strategy, and a focus on pipeline expansion, ITCI is well-equipped to capitalize on market opportunities and drive long-term success.
While facing near-term uncertainties and challenges, ITCI's strategic initiatives and ongoing studies present significant opportunities for expanding its market reach and revenue potential.
Overall, ITCI's commitment to developing innovative medicines and its market acceptance indicate a promising outlook for sustained growth and value creation.

Intra-Cellular Therapies (ITCI) reports robust Q3 performance and eyes market expansion

Intra-Cellular Therapies (ITCI) delivered strong financial performance in Q3 2024, driven by CAPLYTA's sales growth and strategic investments in R&D.
The company's focus on innovation, with new program initiations and pipeline advancements, positions it well for future growth and market expansion.
While facing challenges in a competitive market and cost management, ITCI's solid financial position and promising pipeline offer opportunities for sustained success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm’s lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in Bedminster, NJ.

The pharmaceutical company announced the pricing of a public stock offering. It's wisely taking advantage of a soaring stock price to raise cash ahead of a crucial market launch.

Here's Why Intra-Cellular Therapies Is Sinking Today

The company's first FDA-approved product could be a big hit.

Why Intra-Cellular Therapies Stock Soared 253% in December

Intra-Cellular Therapies Wows Investors With Calypta Win In Schizophrenia

Intra-Cellular Therapies, Inc. (ITCI) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Moving Average Crossover Alert: Intra-Cellular Therapies

The FDA approved the company's schizophrenia drug candidate.

Here's Why Intra-Cellular Therapies Rose as Much as 176.8% Today

Shares of small-cap biopharma Intra-Cellular Therapies Inc (NASDAQ: ITCI) were nearly doubling Monday after a binary event panned out in favor of the company.

Intra-Cellular Therapies Soars To Multiyear High Following FDA Nod For Schizophrenia Drug

Shares of Intra-Cellular Therapeutics rocketed Monday after the Food and Drug Administration approved the biotech company's schizophrenia medicine. The drug will launch in the first quarter.

Why This Highflying Biotech Stock Just Rocketed 160% In Massive Volume

Intra-Cellular Therapy Inc. (NASDAQ: ITCI) shares practically doubled on Monday after the firm announced that the U.S. Food and Drug Administration (FDA) has approved Caplyta for the treatment of schizophrenia in adults.

Why This Schizophrenia Treatment Approval Is Such a Big Deal

Intra-Cellular Therapies Inc. shares ITCI, -0.08% soared 38% in premarket trade Monday, after the company said the U.S.

Intra-Cellular Therapies stock soars 38% premarket after FDA approves schizophrenia treatment

NEW YORK, Dec.  23, 2019  (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that CAPLYTA® (lumateperone) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia in adults. The Company expects to initiate the commercial launch of CAPLYTA in late Q1 2020.

FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults

Investors need to pay close attention to Intra-Cellular Therapies (ITCI) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Intra-Cellular Therapies (ITCI) Stock?

Bipolar depression:  Study 404, A Phase 3 Clinical Trial of lumateperone for the treatment of Bipolar Depression, investigating the potential of lumateperone as a new option for the treatment of depressive episodes in patients suffering from Bipolar I or Bipolar II disorder. 

Intra-Cellular Therapies Highlights Lumateperone Presentations at the 58th Annual Meeting of the American College of Neuropsychopharmacology

Intra-Cellular Therapies (ITCI) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Intra-Cellular Therapies (ITCI) in Focus: Stock Moves 6.1% Higher

Amgen

Amarin Corporation Plc

Bausch Health Companies Inc

FDA announcements can make or break a stock. These four events are the most important ones this month.

4 FDA Dates Biotech Investors Should Circle in December

Allergan

This is your last chance to buy these companies' stocks before the Food and Drug Administration weighs in on the fates of their key candidate treatments.

3 Biotechs Facing FDA Approvals by Year's End

Alector Inc

Athenex

Biohaven Pharmaceutical Hld

Cara Therapeutics

Global Blood Therapeutics

Novartis

Puma Biotechnology

Protagonist Therapeutics

Proteostasis Therapeutics

Rocket Pharma

The remaining weeks of December are chock-full of clinical trial results and FDA approval decisions that savvy investors can take advantage of.

Biotech’s Year-End To-Do List

Intra-Cellular: The Other Side Of The Rainbow

NEW YORK, Dec.  04, 2019  (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that the Company will be presenting at the 58th Annual Meeting of the American College of Neuropsychopharmacology (ACNP) to be held in Hollywood, FL, December 8-11, 2019.

Intra-Cellular Therapies to Present Data on Lumateperone and ITI-333 at the 58th Annual Meeting of the American College of Neuropsychopharmacology

Options Traders Expect Huge Moves in Intra-Cellular Therapies (ITCI) Stock

Intra-Cellular Therapies, Inc. (ITCI) CEO Sharon Mates on Q3 2019 Results - Earnings Call Transcript

As of late, it has definitely been a great time to be an investor Intra-Cellular Therapies.

Intra-Cellular Therapies Shares March Higher, Can It Continue?

Are Options Traders Betting on a Big Move in Intra-Cellular Therapies (ITCI) Stock?

Data indicate ITI-214 at a dose of 30 mg is well tolerated with a favorable safety profile

Intra-Cellular Therapies Announces Progression to Higher Dose Cohort in ITI-214 Translational Medicine Study in Patients with Heart Failure

AC Immune

vTv Therapeutics

Here we discuss six small-cap companies with promising candidates in their pipeline for Alzheimer's disease.

News for Intra-Cellular Therapies Stock (ITCI)